Cerus Corporation (CERS) - Product Pipeline Analysis, 2015 Update

Date: May 13, 2015
Pages: 33
Price:
US$ 750.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C928A61FEC4EN
Leaflet:

Download PDF Leaflet

Cerus Corporation (CERS) - Product Pipeline Analysis, 2015 Update
Summary

Cerus Corporation (Cerus) is a biomedical products manufacturing company. It undertakes the development and commercialization of novel, proprietary products and technologies, intended to make the blood supply safer. The company focuses on the development and commercialization of its flagship Intercept Blood System based on its proprietary Helinx technology. Cerus has the worldwide rights of Intercep7t for three blood components, namely, platelets, red blood cells and plasma. The system is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells (WBC) included in donated blood components intended for transfusion. It markets its product in the US, Europe, Russia, the Middle East and selected countries of other regions of the world for the treatment of both platelets and plasma for transfusions and it is also being developed for the treatment of red blood cells. Cerus is headquartered in Concord, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Cerus Corporation
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Cerus Corporation Company Snapshot
Cerus Corporation Company Overview
Key Information
Cerus Corporation Pipeline Products and Clinical Trials Overview
Cerus Corporation – Pipeline Analysis Overview
Business Description
Key Facts
Cerus Corporation - Major Products and Services
Cerus Corporation Pipeline Products by Development Stage
Cerus Corporation Clinical Trials by Trial Status
Cerus Corporation Pipeline Products Overview
INTERCEPT Blood System - Chikungunya Virus
INTERCEPT Blood System - Chikungunya Virus Product Overview
INTERCEPT Blood System - Chikungunya Virus Clinical Trial
INTERCEPT Blood System - Dengue Virus
INTERCEPT Blood System - Dengue Virus Product Overview
INTERCEPT Blood System - Platelets
INTERCEPT Blood System - Platelets Product Overview
INTERCEPT Blood System - Platelets Clinical Trial
INTERCEPT Blood System For Plasma
INTERCEPT Blood System For Plasma Product Overview
INTERCEPT Blood System For Red Blood Cells
INTERCEPT Blood System For Red Blood Cells Product Overview
Cerus Corporation - Key Competitors
Cerus Corporation - Key Employees
Cerus Corporation - Key Employee Biographies
Cerus Corporation - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Cerus Corporation, Recent Developments
May 05, 2015: Cerus Reports First Quarter 2015 Results
Apr 27, 2015: Cerus To Present At AABB Symposium On Pathogen-Reduced Components
Mar 16, 2015: First Patient Enrolled In Cerus' True Study With The American Red Cross To Address Chikungunya And Dengue Blood Safety Risks With Pathogen Reduced Platelets
Feb 27, 2015: Cerus Signs INTERCEPT Platelet Agreement With Sweden’s Largest Blood Product Supplier
Feb 26, 2015: Cerus Reports Fourth Quarter and Year-End 2014 Results
Jan 28, 2015: Ash Stevens to Manufacture Amotosalen Active Pharmaceutical Ingredient for Cerus' INTERCEPT Blood System
Jan 05, 2015: Cerus Reports EU Phase 3 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint
Dec 22, 2014: Cerus Reports US Phase 2 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint
Dec 18, 2014: FDA Approves INTERCEPT Blood System for Platelets
Dec 16, 2014: Cerus Secures FDA Approval For Intercept Blood Plasma System
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES
Cerus Corporation, Key Facts
Cerus Corporation Pipeline Products and Clinical Trials Overview
Cerus Corporation Pipeline Products by Equipment Type
Cerus Corporation Pipeline Products by Indication
Cerus Corporation Clinical Trials by Trial Status
Cerus Corporation, Key Facts
Cerus Corporation, Major Products and Services
Cerus Corporation Number of Pipeline Products by Development Stage
Cerus Corporation Pipeline Products Summary by Development Stage
Cerus Corporation Clinical Trials by Trial Status
Cerus Corporation Clinical Trials Summary
INTERCEPT Blood System - Chikungunya Virus - Product Status
INTERCEPT Blood System - Chikungunya Virus - Product Description
INTERCEPT Blood System - Chikungunya Virus - True Study to Address Chikungunya and Dengue Blood Safety Risks with Pathogen Reduced Platelets
INTERCEPT Blood System - Dengue Virus - Product Status
INTERCEPT Blood System - Dengue Virus - Product Description
INTERCEPT Blood System - Platelets - Product Status
INTERCEPT Blood System - Platelets - Product Description
INTERCEPT Blood System - Platelets - True Study to Address Chikungunya and Dengue Blood Safety Risks with Pathogen Reduced Platelets
INTERCEPT Blood System For Plasma - Product Status
INTERCEPT Blood System For Plasma - Product Description
INTERCEPT Blood System For Red Blood Cells - Product Status
INTERCEPT Blood System For Red Blood Cells - Product Description
Cerus Corporation, Key Employees
Cerus Corporation, Key Employee Biographies
Cerus Corporation, Subsidiaries

LIST OF FIGURES
Cerus Corporation Pipeline Products by Equipment Type
Cerus Corporation Pipeline Products by Development Stage
Cerus Corporation Clinical Trials by Trial Status
Skip to top


Ask Your Question

Cerus Corporation (CERS) - Product Pipeline Analysis, 2015 Update
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: